Over the past few decades, advances in hematology have illuminated how a delicate balance between stem cell self-renewal and ...

本研究针对急性髓系白血病（AML）和骨髓增生异常综合征（MDS）中适应性免疫疗法（如CAR-T和 checkpoint 抑制剂）疗效有限的 ...

Over the past few decades, advances in hematology have illuminated how a delicate balance between stem cell self-renewal and ...

Myelodysplastic syndrome (MDS) arises from defective blood stem cells that progressively lose their normal functions.

Treosulfan plus fludarabine is approved for alloHSCT in patients with AML or MDS aged 1 year and older. Clinical trial results showed improved overall survival with treosulfan compared to busulfan.

Venclexta-based regimens showed survival benefits in AML and MDS, with a two-year overall survival rate of 46% and median survival of 18.73 months. Remission was achieved by 57.1% of AML patients and ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. So, in terms of preventing MDS, that's a ...

The blood cancers acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are extremely challenging to treat. While advances in immunotherapy have cured many patients with other blood cancers, ...

Investigators say a better understanding of risk factors and categories can help personalize care for patients living with myelodysplastic syndrome (MDS). Men, patients with low absolute neutrophil ...

Progress in the treatment of T-cell blood cancers – which are rare – has also been modest. So, much remains to be done to improve the situation, particularly for patients with myeloid disease. The ...